

OPEN ACCESS

EDITED BY
Cyrille Delpierre,
INSERM Public Health, France

REVIEWED BY Anna Szczerba-Turek, University of Warmia and Mazury in Olsztyn, Poland

*CORRESPONDENCE

David Füller

☑ david.fueller@mhb-fontane.de

RECEIVED 11 March 2024 ACCEPTED 14 May 2024 PUBLISHED 28 May 2024

CITATION

Füller D (2024) Can money buy health? Using a natural experiment to guide interventions to address the socioeconomic inequalities in health. *Front. Public Health* 12:1397127. doi: 10.3389/fpubh.2024.1397127

COPYRIGHT

© 2024 Füller. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Can money buy health? Using a natural experiment to guide interventions to address the socioeconomic inequalities in health

David Füller^{1,2}*

¹Brandenburg Medical School, Brandenburg, Germany, ²Division of Cardiology, Nephrology, and Pulmonology, Department of Internal Medicine, University Hospital Brandenburg an der Havel, Brandenburg Medical School, Brandenburg, Germany

KEYWORDS

socioeconomic factors, natural experiment, social determinants of health, citizen income, health outcomes

Background

In January 2024, the Citizen's Income, a secured payment for people without employment in Germany, has increased by about 12%. This has caused a recent political and social debate because the raise will be significantly higher than the increase in wages and inflation, which as of February 2024 is 2.5% in Germany, the lowest level since June 2021.

An epidemiological and social science perspective

Over the last decades, inequalities in health related to socioeconomic factors including the level of education and income have been highly persistent in Germany, Europe, and in the U.S. (1–3). In particular, a trend of widening disparities in life expectancy by income, associated with an increasingly strong association between low income and poor health, has become evident (2, 3). A disproportional increase of financial resources, e.g., for those receiving the Citizen's Income, can be used as a natural experiment for research purposes which provides the opportunity to examine the health-relevant effects of a significant increase in individual purchasing power. Whether attempting to close the widening gap in financial income in a natural experiment can alleviate disparities in health constitutes a major interest of global public health. In Germany, such natural experiments could be examined using health monitoring data.

Using natural experiments to investigate the significance of the social determinants of health for health-related outcomes is interesting because they can establish causal relationships. In previous work, the causal effects of education on health outcomes in the UK have been assessed using data of the UK Biobank (4). The authors found consistent evidence that raising the minimum school leaving age in the UK in 1972 had beneficial effects on diabetes incidence and mortality risk.

Providing insights from longitudinal studies and natural experiments which focus on the association of socioeconomic determinants and health outcome measures can guide health policy and public health interventions because they can evaluate policy changes and the success or failure of previous interventions. Therefore, they should

Füller 10.3389/fpubh.2024.1397127

include participant-level information on geographical segregation, adverse neighborhood environments, missing opportunities to eat healthy and exercise regularly, duration of unemployment, adverse occupational conditions, and facing discrimination based on sex, age, ethnicity, or poverty, among others, which are associated with an increased risk for ill health.

A clinical perspective

To address socioeconomic inequalities in medicine, along with epidemiological research and public health initiatives, clinical interventions and research evaluating their effects are overdue. Low socioeconomic status is recognized to be a significant risk factor for ill health for many years, however, interventions to mitigate its associated increased risk in adverse health outcomes are rare (5). Previous studies have indicated that the higher allcause mortality risk associated with lower socioeconomic status is comparable to that of physical inactivity, high alcohol intake, obesity, depression, and high cholesterol levels (6, 7). In a subgroup analysis of a randomized clinical trial, it has been shown that health interventions might be particularly effective in patients with lower socioeconomic status (8). For those involved in clinical trials, it is time to plan interventions to avert adverse health outcomes especially in those known to be at increased risk through focus on access to care appropriate to the needs of special populations, reducing barriers in healthcare, improved patient navigation and support, and engagement to collaborate with non-healthcare institutions for the benefit of patients and communities.

Author contributions

DF: Conceptualization, Funding acquisition, Investigation, Validation, Writing – original draft.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The Brandenburg Medical School publication fund supported by the Ministry of Science, Research, and Cultural Affairs of the State of Brandenburg.

Conflict of interest

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

- 1. Mackenbach JP, Valverde JR, Artnik B, Bopp M, Brønnum-Hansen H, Deboosere P, et al. Trends in health inequalities in 27 European countries. *Proc Nat Acad Sci.* (2018) 115:6440–5. doi: 10.1073/pnas.1800028115
- 2. Bor J, Cohen GH, Galea S. Population health in an era of rising income inequality: USA, 1980-2015. *Lancet*. (2017) 389:1475–90. doi: 10.1016/S0140-6736(17)30571-8
- 3. Tetzlaff F, Epping J, Sperlich S, Tetzlaff J. Widening income inequalities in life expectancy? Analysing time trends based on German health insurance data. *J Epidemiol Commun Health*. (2020) 74:592–7. doi: 10.1136/jech-2019-212966
- 4. Davies NM, Dickson M, Davey Smith G, van den Berg GJ, Windmeijer F. The causal effects of education on health outcomes in the UK Biobank. *Nature Human Behavior*. (2018) 2:117–25. doi: 10.1038/s41562-017-0279-y
- Füller D, Jaehn P, Andresen-Bundus H, Pagonas N, Holmberg C, Christ M, et al. Impact of the educational level ons non-fatal health outcomes following myocardial

infarction. Curr Probl Cardiol. (2022) 47:101340. doi: 10.1016/j.cpcardiol.2022. 101340

- 6. Stringhini S, Carmeli C, Jokela M, Avendaño M, Muennig P, Guida F, et al. Socioeconomic status and the 25 × 25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1·7 million men and women. *Lancet.* (2017) 389:1229–37. doi: 10.1016/S0140-6736(16)32380-7
- 7. Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. *Lancet.* (2020) 395:795–808. doi: 10.1016/S0140-6736(19)32008-2
- 8. Fors A, Gyllensten H, Swedberg K, Ekman I. Effectiveness of person-centred care after acute coronary syndrome in relation to educational level: subgroup analysis of a two-armed randomised controlled trial. *Int J Cardiol.* (2016) 221:957–62. doi: 10.1016/j.ijcard.2016.07.060